David C. Sachs - 31 Dec 2022 Form 4 Insider Report for ImmunityBio, Inc. (IBRX)

Role
Chief Financial Officer
Signature
/s/ Jason Liljestrom, as Attorney-in-Fact
Issuer symbol
IBRX
Transactions as of
31 Dec 2022
Net transactions value
$0
Form type
4
Filing time
04 Jan 2023, 20:49:13 UTC
Previous filing
25 Mar 2022
Next filing
28 Aug 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction IBRX Common Stock Options Exercise $0 +7,598 +17% $0.000000 51,298 31 Dec 2022 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction IBRX Restricted Stock Units Options Exercise $0 -7,598 -5.3% $0.000000 136,793 31 Dec 2022 Common Stock 7,598 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit ("RSU") represents a contingent right to receive one share of ImmunityBio, Inc. common stock.
F2 17,242 of the RSUs vested on December 9, 2021. Five percent (5%) of the remaining 151,989 RSUs (rounded down to the nearest whole share) vested on September 9, 2021; five percent (5%) of the RSUs (rounded down to the nearest whole share) vested on December 31, 2022; twenty percent (20%) of the RSUs (rounded down to the nearest whole share) will vest on December 31, 2023; twenty percent (20%) of the RSUs (rounded down to the nearest whole share) will vest on December 31, 2024; twenty percent (20%) of the RSUs (rounded down to the nearest whole share) will vest on December 31, 2025; and the remaining RSUs will vest on December 31, 2026.